Mutations in ARID1A are more commonly associated with endometrioid and clear cell subtypes of endometrial carcinoma, with mutation rates reported between 40 and 50% in endometrioid tumors and 30–50% in clear cell carcinomas [63]. This evidence concerns the gene ARID1A and endometrial carcinoma.